Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2000

View Archived Issues

Phase III efficacy results reported for nalmefene in stroke

NIH awards phase I SBIR grant to Avanir for combination herpes therapy

InterMune Pharmaceuticals commences Actimmune trial in MDR-TB

Scotia licenses rights to Techniclone's VTA technology for use in PDT

SciClone begins marketing and distribution of Zadaxin in Mexico

Beta LT meets safety goals early in clinical trials

Initial trials demonstrate promise of PRO-542 HIV inhibitor

Tourette Syndrome symptoms improve with mecamylamine therapy

Human adenovirus linked to obesity in animals

First use of gene transfer to treat human neurodegenerative disease reported

Ampligen to be considered for orphan drug status in the E.U.

Licensing opportunity from NIH: leukocyte-based inhibition of viral replication

Oxcarbazepine shown to be beneficial in treating refractory partial epilepsy

FDA approves Rescula for treatment of glaucoma

Reminyl receives FDA approvable letter

Pfizer discontinues phase III trials of prinomastat in advanced cancers

PTSD indication sought for Paxil in Canada

Cell Pathways completes phase Ib trial of CP-461

New compounds under development at AstraZeneca for treatment of thrombosis

New compounds interacting with chemokine receptors under study at DuPont

New series of cyclic pyrazine derivatives useful for diabetes

New benzene derivatives useful for pulmonary thrombosis

New TNF inhibitors under development at Daiichi

Novel compounds under study at Melacure Therapeutics for treatment of eating disorders

New PDE5 inhibitors under study at Fujisawa useful for diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...